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Abstract
Cryptophycins are naturally occurring cytotoxins with great potential for chemotherapy. Since targeted therapy provides new
perspectives for treatment of cancer, new potent analogues of cytotoxic agents containing functional groups for conjugation to
homing devices are required. We describe the design, synthesis and biological evaluation of three new unit B cryptophycin ana-
logues. The O-methyl group of the unit B D-tyrosine analogue was replaced by an O-(allyloxyethyl) moiety, an O-(hydroxyethyl)
group, or an O-(((azidoethoxy)ethoxy)ethoyxethyl) substituent. While the former two maintain cytotoxicity in the subnanomolar
range, the attachment of the triethylene glycol spacer with a terminal azide results in a complete loss of activity. Docking studies of
the novel cryptophycin analogues to β-tubulin provided a rationale for the observed cytotoxicities.
Introduction
Cryptophycins are natural occurring cyclic depsipeptides that
were first isolated from cyanobacteria Nostoc sp. ATCC 53789
in 1990 [1]. Cryptophycins target tubulin, in particular the
peptide site of the vinca domain. They block microtubule for-
mation, inhibiting their assembly and, hence, are antimitotic
agents [2,3]. Their high cytotoxicity prompted manifold studies
that were initially focussed on the total synthesis and
structure–activity relationships [4-20]. This work resulted in the
identification of cryptophycin-52, a highly biologically active
analogue of cryptophycin-1 (Figure 1).
Eli Lilly took cryptophycin-52 into clinical trials. Although
almost half of the patients obtained a benefit from the treatment,
neurotoxic side effects forced the termination of the clinical
trials [21-23]. In order to overcome the side effects of crypto-
phycin-52 and to better understand the fundamental structure
for biological activity, numerous structure–activity relationship
studies have been carried out [24-35]. However, like crypto-
phycin-52, the new analogues were not selective against cancer
cells making them not better than its parent.
In recent years the targeted delivery of cytotoxic agents has
emerged as a highly promising method to tackle selectivity
issues [36-40]. Cryptophycin-52 and many analogues lack an
addressable group to conjugate the toxin to a homing device.
For this reason, new analogues containing functional groups
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Scheme 1: Synthesis of modified unit B (13 and 14). Reagents and conditions: (a) 1) TsCl, DMAP, Et3N, CH2Cl2, rt, 4 h; 2) NaN3, DMF, 70 °C,
overnight; (b) TsCl, Et3N, CH2Cl2, rt, overnight; (c) NaI, acetone, reflux, overnight; (d) TsCl, Et3N, CH2Cl2, rt, overnight; (e) NaI, acetone, reflux,
overnight; (f) 6 or 9, K2CO3, DMF, 50 °C, overnight; (g) LiOH, H2O/MeOH/THF 1:1:1, rt, 2 h.
Figure 1: Cryptophycin-1 (1) and -52 (2).
that would allow the conjugation of a homing device were de-
veloped [41-46]. Some of these functionalized analogues have
been recently used for the preparation of antibody–drug conju-
gates (ADCs) and peptide–drug conjugates (PDCs) [46-51].
Nevertheless, there is still a strong need of novel cryptophycin
analogues with maintained activity containing a suitable func-
tional group that would allow the conjugation to the homing
device. Cryptophycin-1 contains a methoxy group in the aro-
matic ring of the unit B, which is a chlorinated derivative of
D-tyrosine. Different chains for unit B have been investigated,
albeit the elongation of the methoxy group is still unknown.
Therefore, in the current study, we embarked on the synthesis of
novel cryptophycin analogues containing different substituents
at the phenolic hydroxy group of the unit B. We intended to in-
vestigate whether the high biological activity of the parent com-
pound is retained and thus, construction of ADCs and PDCs
would be feasible. This preparation could be done using trace-
less cleavable linkers that are sensitive to the distinct physi-
ology of the tumour with enhanced level and activity of specif-
ic enzymes. The connection between the payload and the linker
is of crucial importance since its stability can dramatically
change the release and thus, the activity of the compound. For
this reason, the included functional groups were designed with




Previous docking studies have postulated that the methyl group
of unit B is not involved in the cryptophycin–tubulin interac-
tion [52]. Moreover, its absence did not produce a dramatic loss
of activity [24].
Based on this, we designed cryptophycin analogues modified in
the unit B. Instead of the O-methyl group that is present in the
natural cryptophycin, we attached a hydroxyethyl group or a
triethylene glycol chain terminated with an alcohol or azide, re-
spectively. These functional groups would allow the conjuga-
tion of the novel cryptophycin analogues across an appropriate
linker to an antibody or peptide. Either a virtually uncleavable
triazole (introduced by CuAAC) or scissile ester, carbonate, or
carbamate moieties were taken into account.
The synthesis of the modified unit B (Scheme 1) started with
the preparation of the two different spacers that were later
connected to the phenol. Starting from triethylene glycol (3) or
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Scheme 2: Synthesis of cryptophycin analogues 22, 23 and 24. Reagents and conditions: (a) 4-DMAP, 2,4,6-trichlorobenzoyl chloride, Et3N, THF,
0 °C, 3 h; (b) 1) piperidine, DMF, rt, 2 h; 2) 13 or 14, HOAt, EDC·HCl, Et3N, CH2Cl2, 0 °C → rt, overnight; (c) 1) TFA/CH2Cl2/H2O, rt, 2 h; 2) HATU,
HOAt, DIPEA, DMF, rt, slow addition + 2 h; (d) 1) (CH3O)3CH, PPTS, CH2Cl2, rt, 2 h; 2) AcBr, CH2Cl2, rt, 4 h; 3) K2CO3, DME/ethylene glycol
(2:1 v/v), rt, 5 min; (e) Pd(PPh3)4, phenylsilane, CH2Cl2, rt, 7 h.
2-allyloxyethanol (7) tosylations and nucleophilic displace-
ments by azide or iodide substitution provided 6 and 9 in good
yields. O-Alkylation of Boc-protected 3-chlorinated D-tyrosine
10 with 6 or 9 gave 11 and 12, again in satisfactory yields
(81–85%). Saponification of the ester moiety in 11 and 12 that
was formed concomitantly with the O-alkylation in the previous
reaction provided Boc-protected modified units B 13 and 14 in
76 and 90% yield, respectively.
The synthesis of units C–D and A succeeded as previously de-
scribed in the literature; unit A (15) and C–D (16) were
connected by Yamaguchi esterification to give 17 (Scheme 2)
[45]. Then, Fmoc was cleaved from the N-terminus of unit
C–D–A (17) using piperidine and the resulting crude amine was
coupled to the corresponding modified unit B (13 or 14),
affording the according linear cryptophycins 18 and 19 in
acceptable yields (51–59%). Compounds 18 and 19 were
treated with trifluoroacetic acid for simultaneous Boc and t-Bu
removal, which also cleaved the dioxolane ring. Subsequently,
macrolactamization was performed under pseudo-high-dilution
conditions to afford 20 and 21 as described previously [16].
Then the diol was transformed into the epoxide following a
three-step one-pot reaction as extensively used in the synthesis
of cryptophycin analogues [46]. Cryptophycin analogues 22 and
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2 36.17 36.17 17.21
22 22.61 22.61 5.44
23 32.20 32.20 10.38
24 32.70 32.70 11.72
23 were obtained in good purity after column chromatography.
The allyl ether in 23 was cleaved using Pd(PPh3)4 as Pd(0)
source and phenylsilane as scavenger to obtain the crypto-
phycin analogue 24 in good purity.
Biological evaluation
The biological activity of the modified unit B analogues was de-
termined in a cell viability assay using the human cervix carci-
noma cell line KB-3-1 (Table 1). The cryptophycin analogue 22
showed a dramatic loss of activity compared to cryptophycin-52
(2), while analogues 23 and 24 showed a reduced cytotoxicity
although their IC50 values are still in the low nanomolar range.
The observed dramatic loss of activity of analogue 22 could be
due to its poor internalization or the modification could alter the
interaction with tubulin. In order to get an extensive knowledge
of the novel analogues, we embarked in docking and modelling
studies, herein reported, and internalization studies are ongoing
in our research group.
Table 1: Cytotoxicity of cryptophycin-52 and its unit B analogues.







Docking and modelling of cryptophycin
derivatives
There is no X-ray analysis of cryptophycin–tubulin complexes
available to provide information on the binding site. Based on
biochemical evidence, binding close to the vinca-alkaloid
binding site of β-tubulin, the so called “peptide-site”, has been
proposed [2,52,53]. We performed a docking study to explain
the different affinities of the newly synthesized derivatives. The
parent compound 2 scored highest with respect to β-tubulin
binding (Table 2). Three hydrogen bonds were detected to key
residues in the peptide binding pocket of the vinca domain
(Lys176, Val177 and Tyr210). Other than previously reported
[52], the methoxy group of subunit B forms a hydrogen bond
with Lys176 (Figure 2). Another binding mode of 2 with
high binding affinity and hydrogen bond formation did not
involve any interaction of subunit B, yet it was oriented
towards the GDP binding site that might influence GTP hydro-
lysis.
Figure 2: Binding mode of 2, showing the interaction to the vinca
domain peptide binding pocket (blue). Hydrogen bonds are shown as
yellow dots with the interacting amino acid residues in magenta.
Compound 22 with the triethylene glycol-based substituent
prevents correct binding, the binding energy was decreased and
mainly nonspecific interactions outside the binding pocket were
observed (Figure 3). This was not the case for the other deriva-
tives 23 and 24 (Figure 4).
Figure 3: Docking of 22 to the vinca domain of β-tubulin. Surface and
backbone of β-tubulin are shown in blue, GDP in yellow. No hydrogen
bond formation was detected. The orientation of the azidoethoxy-
ethoxyethyl substituent prevents the inhibitor from the correct interac-
tion with the protein. The epoxide and benzyl group of subunit A are
pointing away from the binding pocket.
Besides hydrogen bond formation and binding affinity of inhibi-
tors 2, 23 and 24, π-interactions and hydrophobic contacts with
the binding pocket of the vinca domain were detected
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Figure 4: Docking of 24 to β-tubulin. Surface and backbone of
β-tubulin are shown in blue, GDP in yellow. H-bonding (yellow dots)
was detected with Lys176 and Asp179 in magenta. The benzyl group
and the epoxide of subunit A are directed towards the peptide binding
pocket, while the hydroxyethyl group is positioned towards the GDP
binding pocket forming an H-bond with Asp179.
that would in turn increase the affinity of the inhibitor and
its effect on the protein (Supporting Information File 1,
Table S1).
Conclusion
In summary, three new cryptophycin analogues with a modi-
fied unit B have been designed and successfully synthesized.
The novel analogues were less active than cryptophycin-52 in
the KB-3-1 cell line. Analogue 22 showed a dramatic loss of ac-
tivity whereas analogues 23 and 24 showed a reduced activity
but were still very cytotoxic.
Supporting Information
Supporting Information File 1
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